Efficacy and Safety of Capmatinib Plus Nivolumab in Pretreated Patients with EGFR Wild-Type Non-Small Cell Lung Cancer

被引：0
|
作者：
Felip, E. [1 ]
Minotti, V. [2 ]
Tan, D. [3 ]
Wolf, J. [4 ]
Mark, M. [5 ]
Boyer, M. [6 ]
Hughes, B. [7 ,8 ]
Bearz, A. [9 ]
Moro-Sibilot, D. [10 ]
Le, X. [11 ]
Vazquez, J. [12 ]
Massuti, B. [13 ]
Liu, N. [14 ]
Hao, L. [14 ]
Cheng, Y. [14 ]
Tiedt, R. [15 ]
Cobo, M. [16 ]
机构：
[1] Vall DHebron Inst Oncol Vhio, Oncol Serv, Barcelona, Spain
[2] AO Perugia Osped S Maria Misericordia Loc S Andre, Perugia, Italy
[3] Natl Canc Ctr Singapore, Singapore, Singapore
[4] Univ Hosp Cologne, Ctr Integrated Oncol, Cologne, Germany
[5] Kantonsspital, Dept Hematol Oncol, Chur, Switzerland
[6] Chris OBrien Lifehouse, Med Oncol, Camperdown, ACT, Australia
[7] Prince Charles Hosp, Chermside, Qld, Australia
[8] Univ Queensland, Brisbane, Qld, Australia
[9] IRCCS Aviano, Aviano, Italy
[10] Ctr Hosp Univ Grenoble Alpes, Grenoble, France
[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[12] Hosp Clin Univ San Carlos, Madrid, Spain
[13] Hosp Gen Univ Alicante, Alicante, Spain
[14] Novartis Inst Biomed Res Co Ltd, Shanghai, Peoples R China
[15] Novartis Inst Biomed Res, Basel, Switzerland
[16] Hosp Univ Carlos Haya, Med Oncol Serv, Malaga, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
PD-L1; inhibitor; MET inhibitor; advanced NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.03
引用
收藏
页码：S585 / S586
页数：2
相关论文
共 50 条
  • [1] Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer
    Felip, Enriqueta
    Metro, Giulio
    Tan, Daniel S. W.
    Wolf, Juergen
    Mark, Michael
    Boyer, Michael
    Hughes, Brett G. M.
    Bearz, Alessandra
    Moro-Sibilot, Denis
    Le, Xiuning
    Puente, Javier
    Massuti, Bartomeu
    Tiedt, Ralph
    Wang, Yingying
    Xu, Chao
    Mardjuadi, Feby I.
    Cobo, Manuel
    [J]. LUNG CANCER, 2024, 192
  • [2] The efficacy of erlotinib for patients with non-small cell lung cancer with wild type of EGFR mutations
    Kobayashi, Takashi
    Koizumi, Tomonobu
    Tanabe, Tsuyoshi
    Tsushima, Kenji
    Urushihata, Kazuhisa
    Yamamoto, Hiroshi
    Hanaoka, Masayuki
    Kubo, Keishi
    Koyama, Shigeru
    Ooura, Nariaki
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S690 - S690
  • [3] A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer Cancer
    Minemura H.
    Yokouchi H.
    Azuma K.
    Hirai K.-I.
    Sekine S.
    Oshima K.
    Kanazawa K.
    Tanino Y.
    Inokoshi Y.
    Ishii T.
    Katsuura Y.
    Oishi A.
    Ishida T.
    Munakata M.
    [J]. BMC Research Notes, 8 (1)
  • [4] EGFR tyrosine kinase inhibitor in advanced non-small cell lung cancer with wild-type EGFR
    Wang, Z.
    Wu, Y. L.
    Yang, J.
    Wang, B.
    Huang, Y.
    Zhou, Q.
    Xu, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] A study of EGFR wild-type non-small cell lung cancer ALK genetic mutation
    Wang, Shoufeng
    Mao, Naiquan
    Zuo, Chuantian
    Pan, Hong
    Xie, Tong
    Huang, Yaoyuan
    Pan, Qi
    Wu, Junwei
    [J]. TRANSLATIONAL CANCER RESEARCH, 2017, 6 (05) : 976 - 980
  • [6] Examination of the importance of RUNX category in EGFR wild-type non-small cell lung cancer
    Kobayakawa, Atsushi
    Takeda, Kanako
    Masuda, Tatuya
    Yanagida, Yohei
    Obi, Natsuno
    Sakuramoto, Naoya
    Hada, Asuka
    Horiuchi, Ayaka
    Takeda, Mizuho
    Sasaki, Asami
    Matsuo, Hidemasa
    Sugiyama, Hiroshi
    Adachi, Souichi
    Kamikubo, Yasuhiko
    [J]. CANCER SCIENCE, 2021, 112 : 445 - 445
  • [7] The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer
    Tanvetyanon, Tawee
    Creelan, Benjamin C.
    Antonia, Scott J.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (09) : 903 - 910
  • [8] Capmatinib for non-small cell lung cancer
    Alzofon, N.
    Jimeno, A.
    [J]. DRUGS OF TODAY, 2021, 57 (01) : 17 - 25
  • [9] Cost of care in EGFR mutant versus wild-type non-small cell lung cancer.
    Vusqa, Urwat Til
    Asawa, Palash
    Miller, Katherine
    Sethi, Ashish
    Rodriguez, Robin Raquel
    Friday, Andrew
    Finley, Gene Grant
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer
    Wang, Duo
    Zhou, Jun
    Fang, Weimin
    Huang, Cuiqing
    Chen, Zerong
    Fan, Meng
    Zhang, Ming-Rong
    Xiao, Zeyu
    Hu, Kuan
    Luo, Liangping
    [J]. BIOACTIVE MATERIALS, 2022, 13 : 312 - 323
12345